SCHEMBL4083898

SCHEMBL4083898

CCOC(=O)c1c(NC(=O)C2(c3ccc(F)cc3)CCCCC2)sc2c1CCOC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR2 O60603 3/20 0.53
MAPT P10636 8/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
CXCR2 P25025 1/20 0.50
ALDH1A1 P00352 6/20 0.47
HSD17B10 Q99714 5/20 0.47
NPSR1 Q6W5P4 5/20 0.47
ALOX15 P16050 3/20 0.47
TSHR P16473 3/20 0.47
MAPK1 P28482 2/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
KDM4E B2RXH2 5/20 0.47
THRB P10828 1/20 0.47
HPGD P15428 3/20 0.47
USP2 O75604 1/20 0.47
PTGER2 P43116 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090895 0.91 TLR2 (0.55) TLR2MAPTKMT2AMEN1CXCR2
SCHEMBL4091708 0.91 ALDH1A1 (0.55) TLR2MAPTALDH1A1HSD17B10NPSR1
SCHEMBL4085480 0.90 PDE4D (0.55) TLR2MAPTKMT2AMEN1CXCR2
SCHEMBL4091378 0.90 MAPT (0.47) TLR2MAPTKMT2AMEN1RXFP1
SCHEMBL4080908 0.87 TLR2 (0.50) TLR2MAPTALDH1A1HSD17B10NPSR1
SCHEMBL4085581 0.86 PTPRC (0.54) MAPTKMT2AMEN1CXCR2ALDH1A1
SCHEMBL4090091 0.85 CNR2 (0.60) TP53ANO1CNR1CNR2
SCHEMBL4090464 0.82 CNR2 (0.53) TLR2MAPTKMT2AALDH1A1HSD17B10
SCHEMBL34468609 0.80 MAPT (0.70) TLR2MAPTKMT2AMEN1RXFP1
SCHEMBL4090883 0.78 RAB7A (0.57) MAPTKMT2AMEN1CXCR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 TLR2 1104/4885MAPT 2527/4885KMT2A 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.